JPH02200639A - Lipid coated bacterium preparation - Google Patents
Lipid coated bacterium preparationInfo
- Publication number
- JPH02200639A JPH02200639A JP1019479A JP1947989A JPH02200639A JP H02200639 A JPH02200639 A JP H02200639A JP 1019479 A JP1019479 A JP 1019479A JP 1947989 A JP1947989 A JP 1947989A JP H02200639 A JPH02200639 A JP H02200639A
- Authority
- JP
- Japan
- Prior art keywords
- powder
- lipid
- bacterium
- bacterial
- bacteria
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000894006 Bacteria Species 0.000 title claims abstract description 36
- 238000002360 preparation method Methods 0.000 title claims abstract description 23
- 150000002632 lipids Chemical class 0.000 title claims abstract description 16
- 239000000843 powder Substances 0.000 claims abstract description 37
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims abstract description 8
- 235000014113 dietary fatty acids Nutrition 0.000 claims abstract description 5
- 229930195729 fatty acid Natural products 0.000 claims abstract description 5
- 239000000194 fatty acid Substances 0.000 claims abstract description 5
- 238000002844 melting Methods 0.000 claims abstract description 5
- 230000008018 melting Effects 0.000 claims abstract description 5
- 229920002472 Starch Polymers 0.000 claims abstract description 4
- 238000004108 freeze drying Methods 0.000 claims abstract description 4
- 235000014655 lactic acid Nutrition 0.000 claims abstract description 4
- 239000004310 lactic acid Substances 0.000 claims abstract description 4
- 239000008107 starch Substances 0.000 claims abstract description 4
- 235000019698 starch Nutrition 0.000 claims abstract description 4
- 241000194017 Streptococcus Species 0.000 claims abstract description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims abstract 2
- 235000013336 milk Nutrition 0.000 claims abstract 2
- 239000008267 milk Substances 0.000 claims abstract 2
- 210000004080 milk Anatomy 0.000 claims abstract 2
- 230000001580 bacterial effect Effects 0.000 claims description 27
- 241000186000 Bifidobacterium Species 0.000 claims description 3
- 241000186660 Lactobacillus Species 0.000 claims description 2
- 230000000968 intestinal effect Effects 0.000 claims description 2
- 229940039696 lactobacillus Drugs 0.000 claims description 2
- 125000005313 fatty acid group Chemical group 0.000 claims 1
- 239000002245 particle Substances 0.000 abstract description 10
- 239000003921 oil Substances 0.000 abstract description 8
- 238000002156 mixing Methods 0.000 abstract description 6
- 239000002253 acid Substances 0.000 abstract description 3
- 150000004665 fatty acids Chemical class 0.000 abstract description 3
- 239000003925 fat Substances 0.000 abstract description 2
- 239000001993 wax Substances 0.000 abstract description 2
- 241000193830 Bacillus <bacterium> Species 0.000 abstract 1
- 210000000936 intestine Anatomy 0.000 abstract 1
- 229940068140 lactobacillus bifidus Drugs 0.000 abstract 1
- 239000011248 coating agent Substances 0.000 description 15
- 238000000576 coating method Methods 0.000 description 13
- 238000004519 manufacturing process Methods 0.000 description 8
- 238000000034 method Methods 0.000 description 7
- 230000002378 acidificating effect Effects 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 239000003814 drug Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 4
- 241000194032 Enterococcus faecalis Species 0.000 description 3
- 240000001046 Lactobacillus acidophilus Species 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 241001608472 Bifidobacterium longum Species 0.000 description 2
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 description 2
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 2
- 229940009291 bifidobacterium longum Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 241000186012 Bifidobacterium breve Species 0.000 description 1
- 241000186015 Bifidobacterium longum subsp. infantis Species 0.000 description 1
- 229910001369 Brass Inorganic materials 0.000 description 1
- 240000002791 Brassica napus Species 0.000 description 1
- 235000004977 Brassica sinapistrum Nutrition 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 244000199885 Lactobacillus bulgaricus Species 0.000 description 1
- 235000013960 Lactobacillus bulgaricus Nutrition 0.000 description 1
- 244000199866 Lactobacillus casei Species 0.000 description 1
- 235000013958 Lactobacillus casei Nutrition 0.000 description 1
- 241001147746 Lactobacillus delbrueckii subsp. lactis Species 0.000 description 1
- 244000057717 Streptococcus lactis Species 0.000 description 1
- 235000014897 Streptococcus lactis Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229940004120 bifidobacterium infantis Drugs 0.000 description 1
- 239000010951 brass Substances 0.000 description 1
- 235000020299 breve Nutrition 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- -1 fatty acid monoglycerides Chemical class 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 229940004208 lactobacillus bulgaricus Drugs 0.000 description 1
- 229940017800 lactobacillus casei Drugs 0.000 description 1
- 239000011812 mixed powder Substances 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 210000004798 organs belonging to the digestive system Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
【発明の詳細な説明】
［産業上の利用分野］
本発明は、改良された製剤により製造された経口投与可
能な医薬として用いられる細菌製剤に関するものである
。DETAILED DESCRIPTION OF THE INVENTION [Industrial Field of Application] The present invention relates to a bacterial preparation prepared by an improved formulation and used as an orally administrable medicine.
［従来の技術］
腸内細菌が、人間の体内、特に小腸以降の消化器官で人
間の消化活動に有用な効果を示すことが知られている（
以下、この様な細菌を石川細菌と称す）。この石川細菌
を経口投Ｉｉ、することにより薬理にの効果を期待し得
ることも広く知られている。[Prior Art] It is known that intestinal bacteria have a beneficial effect on human digestive activity in the human body, especially in the digestive organs starting from the small intestine.
Hereinafter, such bacteria will be referred to as Ishikawa bacteria). It is also widely known that pharmacological effects can be expected by oral administration of Ishikawa bacteria.
しかし、一般に、これら有用細菌類は、酸性雰囲気下で
は生存することが難しく、経口により有用細菌類を人間
に投与しても、胃酸等の作用によりほとんど死滅してし
まう。However, in general, it is difficult for these useful bacteria to survive in an acidic atmosphere, and even if useful bacteria are administered orally to humans, most of them will die due to the action of stomach acid and the like.
これを回避するための改良法が提案されている（特開昭
６２−２６３１２８号）。これは、有用細菌を３層のシ
ームレスカプセルとする方法である。しかしながら、こ
れら従来の製造方法は、極めて煩雑であり、製造上困難
なうえ、コスト面でも高価となり、実用には程遠いもの
であった。An improved method has been proposed to avoid this problem (Japanese Patent Application Laid-open No. 263128/1982). This is a method to make useful bacteria into a three-layer seamless capsule. However, these conventional manufacturing methods are extremely complicated, difficult to manufacture, and expensive in terms of cost, and are far from practical.
［発明が解決しようとする課題］
本発明は、上記従来技術における問題点を解決するため
のもので、酸性雰囲気下では極めて不安定な有用細菌を
、実用的な製造方法と製造コストで改良し、工業的に経
口投与可能な有用細菌製剤として提供すること、及びそ
の医薬としての利用を可能にすることを課題としている
。[Problems to be Solved by the Invention] The present invention is intended to solve the above-mentioned problems in the prior art, and aims to improve useful bacteria that are extremely unstable in an acidic atmosphere using a practical manufacturing method and manufacturing cost. The object of the present invention is to provide a useful bacterial preparation that can be industrially administered orally, and to enable its use as a medicine.
従って本発明は、医薬として実用的に利用し得る、経口
投与可能な有用細菌製剤の提供を目的としている。Therefore, the present invention aims to provide an orally administrable useful bacterial preparation that can be practically used as a medicine.
［課題を解決するための手段］
本発明者等は、上記課題の工業的に経口投与可能な有用
細菌製剤を得るべく鋭意研究した結果、有用細菌を実質
的に被覆可能な被覆剤を見出し、本発明を完成した。す
なわち本発明は、融点４０℃以上の脂質粉体な接触、又
は衝突により細菌粉体粒子の全周囲表面に脂質を付着さ
せ、有用細菌を遣方法と製造コストで、工業的に経口投
与可能な有用細菌製剤とし、その医薬としての利用を可
能にするものである。[Means for Solving the Problem] As a result of intensive research to obtain an industrially orally administrable useful bacterial preparation for the above-mentioned problem, the present inventors discovered a coating material that can substantially coat useful bacteria, The invention has been completed. That is, the present invention allows lipids to be attached to the entire peripheral surface of bacterial powder particles by contact or collision with lipid powder having a melting point of 40° C. or higher, and to produce useful bacteria that can be industrially orally administered using a method and manufacturing cost. The present invention provides a useful bacterial preparation and enables its use as a medicine.
本発明を利用し得る有用細菌としては、ビフィドバクテ
リウム ビフィズス（Ｂｉｆｉｄｏｂａｃｔｅｒｉｕｍ
ｂｉｆｉｄｕｓ ） 、 ビフィドバクテリウム ロ
ンガム（Ｂ、 ｌｏｎｇｕ曹）、ビフィドバクテリウム
アドレスセンチイス（Ｂ、 ａｄｏｌｅｓｃｅｎｔｉ
ｓ ） 、 ビフィドバクテリウム ブレベ（ｆ３．
ｂｒｅｖｅ ）、ビフィドバクテリウム インファン
ティス（Ｂ、 １ｎｆａｎｔｉｓ ） 等のビフィズス
菌、ラクトバチルス アシドフィルス（Ｌａｃｔｏｂａ
ｃｉｌｌｕｓ ａｃｉｄｏｐｈｉｌｕｓ ） 、ラクト
バチルス ラクチス（Ｌ、 Ｉａｃｔｉｓ ） 、 ラ
クトバチルスカゼイ（Ｌ、 ｃａｓｅｉ ）、ラクトバ
チルス ブルガリクス（Ｌ、 ｂｕｌｇａｒｉｃｕｓ
）等の乳酸桿菌、ストレプトコッカス ラクティス（５
ｔｒｅｐｔｏｃｏｃｃｕｓ Ｉａｃｔｉｓ）、及びスト
レプトコッカス フェカリス（Ｓ。Examples of useful bacteria that can be used in the present invention include Bifidobacterium bifidus.
bifidus), Bifidobacterium longum (B.
s), Bifidobacterium breve (f3.
breve), bifidobacteria such as Bifidobacterium infantis (B, 1nfantis), and Lactobacillus acidophilus (Lactobacillus acidophilus).
cillus acidophilus), Lactobacillus lactis (L, Iactis), Lactobacillus casei (L, casei), Lactobacillus bulgaricus (L, bulgaricus)
), Streptococcus lactis (5
Streptococcus Iactis), and Streptococcus faecalis (S.
ａｅｃａｌｉｓ ）等の乳酸菌、等の菌があげられる。Examples include lactic acid bacteria such as L. aecalis.
これらの細菌は、通常の方法を用い、Ｍ酵培養液から遠
心分離法等の手段によって集菌し、急速凍結後、高真空
雰囲気下において乾燥する、いわゆる凍結乾燥により粉
状体としたものが用いられる。この際、菌の状態によっ
ては、Ｌ−乳酸、脱脂粉乳、澱粉等の可食性粉を凍結前
、又は後に混入したものを用いることもできる。These bacteria are collected using conventional methods such as centrifugation from the M fermentation culture solution, quickly frozen, and then dried in a high vacuum atmosphere to form a powder through so-called freeze-drying. used. At this time, depending on the state of the bacteria, edible powder such as L-lactic acid, skim milk powder, or starch may be mixed in before or after freezing.
上記細菌粉体の粒径は、通常０．５ Ｆｍｌ〜１．０ｍ
ｍのものが好ましい。又、その形状は球型、もしくは不
定型であっても使用することができる。被覆剤として用
いられる本発明の脂質粉体としては、融点４０℃以上の
天然油脂、硬化油、ワックス、脂肪酸モノグリセリド、
脂肪酸ジグリセリド、脂肪酸その他、食用油脂が使用で
き、これらの１種又は２種以上を混合して用いることも
できる。The particle size of the above bacterial powder is usually 0.5 Fml to 1.0 m.
m is preferred. Moreover, the shape can be spherical or irregular. The lipid powder of the present invention used as a coating material includes natural oils and fats with a melting point of 40°C or higher, hydrogenated oils, waxes, fatty acid monoglycerides,
Fatty acid diglycerides, fatty acids, and other edible fats and oils can be used, and one type or a mixture of two or more of these can also be used.
細菌粉体と被覆剤との粒径比は、ｌ：１から： ０．０
００１が好ましく用いられる。又、混合比は重量比で０
．５〜５０の範囲で用いることが可能であるが、粒径比
との関係で調整することが望ましい。すなわち、被覆剤
が細菌粉体粒子の全周囲衣１面にまんべんなく付着・被
覆するように、適時条件を選択し決定する。The particle size ratio of bacterial powder and coating agent is from 1:1 to 0.0.
001 is preferably used. Also, the mixing ratio is 0 in terms of weight ratio.
．． Although it is possible to use it in the range of 5 to 50, it is desirable to adjust it in relation to the particle size ratio. That is, appropriate conditions are selected and determined so that the coating agent evenly adheres to and coats the entire surface of the bacterial powder particles.
［実施例］
以下、実施例に基づき、本発明の詳細な説明するが、こ
れにより本発明の範囲が限定されるものではない。[Examples] Hereinafter, the present invention will be described in detail based on Examples, but the scope of the present invention is not limited thereby.
実施例１゜
凍結乾燥処理を施した、ビフィドバクテリウムロンガム
（以下、Ｂ、 Ｉｏｎｇｕ薦と略称する）と澱粉の混合
粉体（Ｂ、 Ｉｏｎｇｕｍ １．３ Ｘ １０９個／ｇ
’ｔＢ粉）４２ｇ（平均粒径１１０１３１１ ）と菜種
硬化油（平均粒径８．６Ｆ、融点６４．１’Ｃ：日本油
脂株式会社製）２１ ｇを真ちゅう製のポール２０個と
共に、遠心回転型混合機（タカノミルＭＭＩＯ：開田精
工社製）に入れ１回転速度３００ ｒ、ｐ、＋＊、で４
時間混合し、被覆製剤６３ ｇを得た。得られた被覆製
剤の表面を電子！ｒＩ微鏡で観察した所、極めて良好な
被覆が形成されていることを認めた。Example 1 Lyophilized mixed powder of Bifidobacterium longum (hereinafter referred to as B, Iongum) and starch (B, Iongum 1.3 x 109 pieces/g)
'tB powder) 42 g (average particle size 1101311) and 21 g rapeseed hydrogenated oil (average particle size 8.6F, melting point 64.1'C: manufactured by Nippon Oil & Fats Co., Ltd.) were mixed together with 20 brass poles in a centrifugal rotating type. Place in a mixer (Takano Mill MMIO: manufactured by Kaida Seiko Co., Ltd.) and mix at a rotational speed of 300 r, p, +*, 4
After mixing for a period of time, 63 g of coated formulation was obtained. Electron the surface of the resulting coated preparation! When observed with an rI microscope, it was found that an extremely good coating was formed.
更に、被覆製剤されたＢ、 １ｏｃｕｓの生菌数を測定
したところ、Ｂ、Ｉｏｎｇｕｍ Ｏ，９Ｘ １０９個／
ｇ製剤でｉす、被覆処理に伴う損失率は、はとんどなく
、２ノ
凍結乾燥生菌が被覆工程で安定的に処理されていること
を確認した。Furthermore, when the number of viable bacteria of B, 1 ocus of coated preparation was measured, it was found that B, Iongum O, 9X 109 cells/
It was confirmed that the loss rate associated with the coating process was almost negligible with the G formulation, and that the two freeze-dried live bacteria were stably treated in the coating process.
実施例２゜
酸性下とするために、人工胃酸液としてモデル的に作成
した、３７℃に保ったｐＨ４，０、及びｐＨ５，０のリ
ン酸緩衝液中に ０．１重量％の未処理のＢ。Example 2 In order to create an acidic environment, 0.1% by weight of untreated raw material was added to a phosphate buffer solution of pH 4.0 and pH 5.0 maintained at 37°C, which was prepared as a model as an artificial gastric acid solution. B.
Ｉｏｍｇｕ■粉体、並びに被覆剤に硬化油を使用し、細
菌粉体と被覆剤の混合比を１：１とした他は、実施例１
に準じて被覆製剤としたＢ、 ｌｏ■ｇｕｍ （被覆化
処理Ｂ、 Ｉｏｎｇｕｍ）を投入し、攪拌しながら所定
時間毎の生存菌数を公知の方法により測定し、投入直後
（０分間）の生存菌数を １００とした生存率（％）で
表わした結果を第１表、及び第２表に示す。Example 1 except that hydrogenated oil was used as the Iomgu powder and coating material, and the mixing ratio of bacterial powder and coating material was 1:1.
B, logum (coating treatment B, Iongum), which was made into a coating preparation according to the above, was added, and while stirring, the number of viable bacteria was measured at predetermined time intervals by a known method. Tables 1 and 2 show the results expressed as survival rate (%) with the number of bacteria as 100.
第１表の結果より、未処理のＢ、 ｌｏｍｇｕｍが短期
間のうちに死滅した状態にあるのに対し１本発明の被覆
化処理Ｂ、 ｌｏｍｇｕｍは、はぼ安定な生存状態を示
していることが確認された。又、第２表の結されないこ
とが確認された。From the results in Table 1, it can be seen that while the untreated B. lomgum died in a short period of time, the coated B. lomgum of the present invention showed a fairly stable survival state. was confirmed. It was also confirmed that Table 2 was not concluded.
以下余白
実施例３゜
３７℃に保ったｐＨ６，９とｐｏ ５．０のリン酸緩衝
液中に０．１重量％の未処理のストレプトコッカス フ
ェカリス（以下、Ｓ、 ｆａｅｃａｌｉｓと略称する）
粉体並びに被覆剤に硬化油を使用し、細菌粉体と被覆剤
の混合比を６＝４とした他は、実施例１に準じ生存菌数
な公知の方法により測定し、投入直後（０分間）の生存
菌数を ｉｏｏとした生存率（％）で表わした結果を第
３表、及び第４表に示す。Example 3: 0.1% by weight of untreated Streptococcus faecalis (hereinafter abbreviated as S. faecalis) in a phosphate buffer with pH 6.9 and po 5.0 kept at 37°C.
The number of viable bacteria was measured by a known method in accordance with Example 1, except that hydrogenated oil was used for the powder and coating material, and the mixing ratio of bacterial powder and coating material was 6=4. Tables 3 and 4 show the results expressed as survival rate (%), where the number of viable bacteria per minute was ioo.
第３表の結果より、中性下（ｐＨ６，９）において未処
理のＳ、 ｆａｅｃａｌｉｓは、やや減少する傾向を示
すが、被覆処理Ｓ、 ｆａｅｃａｌｉｓは全く影響され
ないことが確認された。又、第４表の結果より、酸性下
（ｐＨ５，０）において、未処理のＳ、 ｆａｅｃａｌ
ｉｓは、著しく減少する傾向を示すが、被覆処理Ｓ、
ｆａｅｃａｌｉｇは比較的影響されないことが確認され
た。From the results in Table 3, it was confirmed that under neutral conditions (pH 6, 9), untreated S and faecalis tended to decrease slightly, but coated S and faecalis were not affected at all. Also, from the results in Table 4, under acidic conditions (pH 5, 0), untreated S, faecal
is shows a tendency to decrease significantly, but after coating treatment S,
faecalig was found to be relatively unaffected.
以下余白
実施例４゜
３７℃に保ったｐＨ６，９とｐＨ５，０のリン酩緩衝液
中に０．１重量％の未処理のラクトバチルス アシド７
４ルス（以下、Ｌ、 ａｃｉｄｏｐｈｉｌｕｓと略称す
る ）、並びに被覆剤に硬化油を使用し、細菌粉体と被
覆剤の混合比を４：６とした他は、実施例１に準じて被
覆製剤としたり、 ａｃｉｄｏｐｈｉｌｕｓ （被覆化
処理り、 ａｃｉｄｏｐｈｉｌｕｓ ）を投入し、攪拌
シナカラ所定時間毎の生存菌数を公知の方法により測定
し、投入直後（０分間）の生存菌数を１００とした生存
率（％）で表わした結果を第５表、及び第６表に示す。Margin below Example 4: 0.1% by weight of untreated Lactobacillus acid 7 in phosphorous buffer solutions of pH 6.9 and pH 5.0 maintained at 37°C.
A coating preparation was prepared according to Example 1, except that L. acidophilus (hereinafter abbreviated as L) and hydrogenated oil were used as the coating agent, and the mixing ratio of bacterial powder and coating agent was 4:6. Or, Acidophilus (coated treated, Acidophilus) was added, and the number of viable bacteria was measured at each predetermined time while stirring, using a known method. ) The results are shown in Tables 5 and 6.
第５表の結果より、中性下（ｐＨ６，９）において未処
理のり、 ａｃｉｄｏｐｈｉｌｕｓは、やや減少する傾
向を示すが、被覆処理り、 ａｃｉｄｏｐｈｉｌｕｓは
、はとんど影響されないことが確認された。又、第６表
の結果より、酸性下（ｐＨ５，０）においても、未処理
のり、 ａｃｉｄｏｐｈｉｌｕｓはやや減少する傾向を
示すが、被覆処理り、 ａｃｉｄｏ−ｐｈｉｌｕｓは、
はとんど影響されないことが確認された。From the results in Table 5, it was confirmed that under neutral conditions (pH 6, 9), untreated acidophilus tended to decrease slightly, but coated acidophilus was hardly affected. Also, from the results in Table 6, even under acidic conditions (pH 5, 0), untreated acidophilus tends to decrease slightly, but coated acidophilus tends to decrease.
It was confirmed that it was not affected at all.
［試験例］
実施例１と同様の方法により作成した被覆細菌製剤Ｂ、
Ｉｏｎｇｕｍ、並びに未処理Ｂ、 Ｉｏｎｇｕ＋ｗを
密閉した容器で室温に保存して、それらの経時的な安定
性を測定した。製造時の生存菌数を１００とした１、３
．６．及び９ケ月後の各々の時点における生存率（％）
で表わした結果を第７表に示した。[Test Example] Coated bacterial preparation B prepared by the same method as Example 1,
Iongum, as well as untreated B, Iongu+w, were stored at room temperature in closed containers to determine their stability over time. 1, 3 with the number of viable bacteria at the time of production being 100
．． 6. and survival rate (%) at each time point after 9 months
The results expressed in Table 7 are shown in Table 7.
第７表の結果より、本発明の被覆細菌製剤は、いずれの
時点においても、未処理細菌に比較して経時的な保存安
定性に優れていることが確認された。From the results in Table 7, it was confirmed that the coated bacterial preparation of the present invention had superior storage stability over time compared to untreated bacteria at any time point.
以下余白
］５
［発明の効果］
上述の如く、本発明の被覆細菌製剤は、従来の細菌製剤
に比べ、製造が極めて容易であり、従って製造時間とコ
ストの大幅な軽減を可能にする。Margins below] 5 [Effects of the Invention] As described above, the coated bacterial preparation of the present invention is extremely easy to manufacture compared to conventional bacterial preparations, and therefore enables a significant reduction in manufacturing time and cost.
又、従来の細菌製剤の弱点であった、酸性下に＼おけ６
安定性が向上１・経１投与可能′医薬とし゛に効果的に
用いることができる。更に、外気や水分との遮断、及び
他の成分との接触の防止が可能になり、保存安定性にも
優れる等、商品価値を向上する有用な効果を奏するもの
である。In addition, the drawback of conventional bacterial preparations is that they cannot be placed under acidic conditions6.
It has improved stability and can be effectively used as a medicine that can be administered orally. Furthermore, it is possible to block out external air and moisture, prevent contact with other components, and have excellent storage stability, which has useful effects that improve commercial value.
Claims (1)
食性粉体を含む混合細菌粉体に、少なくとも一種以上の
、融点４０℃以上の脂質粉体を接触又は、衝突により上
記細菌粉体粒子の全周囲表面に付着させてなることを特
徴とする脂質被覆細菌製剤 ２）細菌粉体が、腸内細菌であることを特徴とする請求
項１記載の脂質被覆細菌製剤 ３）腸内細菌が、ビフィズス菌、乳酸桿菌、酵母菌、ス
トレフトコッカス属に属する菌の群から選ばれることを
特徴とする請求項２記載の脂質被覆細菌製剤 ４）細菌粉体が、粒径０．５μｍ〜１ｍｍの範囲で選ば
れることを特徴とする請求項１記載の脂質被覆細菌製剤 ５）可食性粉体が、乳酸、粉乳、澱粉の群から選ばれる
１種以上の粉体であることを特徴とする請求項１記載の
脂質被覆細菌製剤 ６）脂質粉体が、脂肪酸、あるいは硬化油等の食用油脂
であることを特徴とする請求項１記載の脂質被覆細菌製
剤 ７）経口投与可能な医薬として用いることを特徴とする
請求項１、２、３、４、５、又は６記載の脂質被覆細菌
製剤[Claims] 1) At least one kind of lipid powder having a melting point of 40°C or more is brought into contact with the bacterial powder itself or the mixed bacterial powder containing edible powder, which has been powdered by freeze-drying. 2) The lipid-coated bacterial preparation according to claim 1, characterized in that the bacterial powder is an enteric bacterium. Bacterial preparation 3) The lipid-coated bacterial preparation according to claim 2, wherein the intestinal bacteria are selected from the group of bacteria belonging to the genus Bifidobacteria, Lactobacillus, Yeast, and Streptococcus 4) The bacterial powder is 5) The lipid-coated bacterial preparation according to claim 1, wherein the edible powder is one or more powders selected from the group of lactic acid, milk powder, and starch. 6) The lipid-coated bacterial preparation according to claim 1, wherein the lipid powder is a fatty acid or an edible fat such as hydrogenated oil. ) The lipid-coated bacterial preparation according to claim 1, 2, 3, 4, 5, or 6, characterized in that it is used as an orally administrable pharmaceutical.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP1019479A JPH02200639A (en) | 1989-01-31 | 1989-01-31 | Lipid coated bacterium preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP1019479A JPH02200639A (en) | 1989-01-31 | 1989-01-31 | Lipid coated bacterium preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH02200639A true JPH02200639A (en) | 1990-08-08 |
Family
ID=12000476
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP1019479A Pending JPH02200639A (en) | 1989-01-31 | 1989-01-31 | Lipid coated bacterium preparation |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH02200639A (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997016077A1 (en) * | 1995-11-02 | 1997-05-09 | Ed. Haas Nährmittel Gesellschaft Mbh | Probiotically acting formulations |
| JP2006521334A (en) * | 2003-03-24 | 2006-09-21 | オラランス ファルマ | Novel galenical formulation system, preparation method and use for active ingredient transport |
| CN103347395A (en) * | 2010-12-06 | 2013-10-09 | 德嘉玛贝里尔有限公司 | Composition and method for improving stability and extending shelf life of probiotic bacteria and food products thereof |
| JP2014534959A (en) * | 2011-10-14 | 2014-12-25 | ディーエスエム アイピー アセッツ ビー．ブイ． | New coating system |
| WO2020196844A1 (en) | 2019-03-28 | 2020-10-01 | 森永乳業株式会社 | Heat-resistant bacterium composition |
| WO2021152869A1 (en) * | 2020-01-28 | 2021-08-05 | ナットリオミックス，インコーポレイテッド | Enteric composition, food/beverage item containing said enteric composition, method for controlling disintegration time for said enteric composition, and method for manufacturing said enteric composition |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH02142735A (en) * | 1988-11-24 | 1990-05-31 | Nippon Oil & Fats Co Ltd | Highly stable intestinal useful bacterial pharmaceutical and production thereof |
-
1989
- 1989-01-31 JP JP1019479A patent/JPH02200639A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH02142735A (en) * | 1988-11-24 | 1990-05-31 | Nippon Oil & Fats Co Ltd | Highly stable intestinal useful bacterial pharmaceutical and production thereof |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997016077A1 (en) * | 1995-11-02 | 1997-05-09 | Ed. Haas Nährmittel Gesellschaft Mbh | Probiotically acting formulations |
| JP2006521334A (en) * | 2003-03-24 | 2006-09-21 | オラランス ファルマ | Novel galenical formulation system, preparation method and use for active ingredient transport |
| US8911788B2 (en) | 2003-03-24 | 2014-12-16 | Capsugel France SAS | Galenical system for active transport, method for preparation and use |
| CN103347395A (en) * | 2010-12-06 | 2013-10-09 | 德嘉玛贝里尔有限公司 | Composition and method for improving stability and extending shelf life of probiotic bacteria and food products thereof |
| JP2014534959A (en) * | 2011-10-14 | 2014-12-25 | ディーエスエム アイピー アセッツ ビー．ブイ． | New coating system |
| WO2020196844A1 (en) | 2019-03-28 | 2020-10-01 | 森永乳業株式会社 | Heat-resistant bacterium composition |
| WO2021152869A1 (en) * | 2020-01-28 | 2021-08-05 | ナットリオミックス，インコーポレイテッド | Enteric composition, food/beverage item containing said enteric composition, method for controlling disintegration time for said enteric composition, and method for manufacturing said enteric composition |
| JP2021114952A (en) * | 2020-01-28 | 2021-08-10 | ナットリオミックス, インコーポレイテッドNutriomix, Inc. | Enteric composition, food/beverage containing enteric composition, method for controlling disintegration time for enteric composition, and method for manufacturing enteric composition |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU694227B2 (en) | Stabilized biologically active compounds contained in coated microgranules which can be suspended in alimentary fluids | |
| AU2010222618B2 (en) | Oily suspension containing probiotic bacteria for paediatric uses | |
| CN100469869C (en) | Embedding protection method for beneficial bacteria of intestinal tract | |
| RU2214258C2 (en) | Absorption of mineral substances by intestinal cells | |
| CN108783462A (en) | A kind of industrial process of beneficial bacteria of intestinal tract preparation | |
| JP3720780B2 (en) | Method for producing double-coated lactic acid bacteria powder using protein and polysaccharide | |
| AU778946B2 (en) | Composition comprising alkaline sphingomyelinase for use as a dietetic preparation, food supplement or pharmaceutical product | |
| KR20130067682A (en) | Method of preparing quadruple-coating lactic acid bacteria and quadruple-coating lactic acid bacteria prepared thereby | |
| JP2003501399A5 (en) | ||
| EP1514553A1 (en) | Lactic acid bacteria powder double-coated using protein and polysaccharide and method preparing the same and a dosage form thereof | |
| KR20150056107A (en) | Method for preparing coated lactic acid bacteria | |
| Mabrouk et al. | Preparation of symbiotic whey protein gel as a carrier of free and encapsulated probiotic bacteria | |
| KR20180129168A (en) | Natural liposome comprising lactic acid bacteria, process for the preparation thereof and food or pharmaceutical composition comprising the same | |
| JPH02200639A (en) | Lipid coated bacterium preparation | |
| JPH0649654B2 (en) | Highly stable enteric useful bacterial preparation and method for producing the same | |
| JP2003012526A (en) | Pharmaceutical preparation including useful live bacterium | |
| WO2019026743A1 (en) | Thickening composition for dysphagia patients | |
| JP7499704B2 (en) | Probiotic composition with storage stability and resistance to gastric juice degradation | |
| JP2004250338A (en) | Useful live bacterium pharmaceutical preparation | |
| Hati et al. | Encapsulation of probiotics for enhancing the survival in gastrointestinal tract | |
| CN110279118A (en) | A kind of compound probiotic composition, compound probiotic freeze-dried powder capsule and preparation method | |
| RU2795965C1 (en) | Method for manufacturing encapsulated form of a probiotic food supplement | |
| JP4121306B2 (en) | Viable bacteria | |
| CN114762527B (en) | Tasty and refreshing tablet containing active probiotics and preparation method thereof | |
| JP3222391U (en) | Coating structure of plant fermentation broth |